CS Cancer Solutions - Structured Oncology Intelligence
Mexico flag

Mexico Cancer Research

International Collaboration Leader & Cervical Cancer Pioneer

90%+

Cervical Cancer Reduction

20-year breakthrough study

1st

CAR-T in Latin America

Pilot programs launched

200%

Screening Rate Increase

Breast cancer awareness

Major Research Achievements

20-Year Cervical Cancer Clinical Trial Breakthrough

2004-2024

Mexico completed a landmark 20-year clinical trial proving HPV vaccination combined with screening reduces cervical cancer incidence by 90%+. This study influences global policy.

Instituto Nacional de Cancerología (INCan)

Impact:

Shaping global cervical cancer prevention strategies

CAR-T Therapy Pilot Programs

2023-2024

Mexico launched Latin America's first CAR-T therapy pilot programs in partnership with US institutions, bringing advanced immunotherapy to Mexican patients at lower costs.

Hospital Ángeles, INCan

Impact:

Democratizing CAR-T access in Mexico

US NCI-Funded Cancer Research Programs

Ongoing

Mexico partners with the US National Cancer Institute on cross-border research studying cancer genetics in Hispanic/Latino populations.

INCan, Centro Médico Nacional Siglo XXI

Impact:

Improving cancer care for 60+ million Hispanic Americans

Affordable Generic Drug Production

Ongoing

Mexico manufactures high-quality generic cancer drugs for North and Latin America, reducing treatment costs by 70%+.

Mexican pharmaceutical companies

Impact:

Making cancer treatment affordable across the Americas

Telemedicine Oncology Network

2020-2024

Mexico built a nationwide telemedicine network connecting rural patients to oncology specialists in Mexico City, serving millions in underserved areas.

Mexican Ministry of Health

Impact:

Eliminating geographic barriers to cancer care

Breast Cancer Awareness & Early Detection Campaigns

2014-2024

Mexico's massive public health campaigns increased breast cancer screening rates by 200% in 10 years, saving thousands of lives annually.

Mexican Cancer Society

Impact:

Catching breast cancer earlier when it's most curable

Leading Research Institutions

Instituto Nacional de Cancerología (INCan)

Mexico City

Mexico's premier cancer institute. Leading research in cervical, breast, and pediatric cancers. Strong partnerships with US NCI and international organizations.

Key Specialties:

Cervical Cancer
Breast Cancer
Pediatric Oncology
HPV Prevention

Centro Médico Nacional Siglo XXI

Mexico City

Major public hospital conducting cancer research for Mexico's social security system. Focus on accessible, affordable cancer care.

Key Specialties:

Public Health Oncology
Cancer Genetics
Affordable Care Models

Hospital Ángeles Pedregal

Mexico City

Private hospital pioneering CAR-T therapy and advanced immunotherapy in Mexico. International partnerships for clinical trials.

Key Specialties:

CAR-T Therapy
Immunotherapy
International Clinical Trials
Active Clinical Trials in Mexico

Mexico welcomes international patients to cutting-edge clinical trials

CAR-T for Leukemia (Mexico-US Partnership)

Phase 2

Testing CAR-T cell therapy for pediatric and adult leukemia patients in partnership with US cancer centers.

Hospital Ángeles, INCan
Active recruitment

HPV Vaccination Long-term Efficacy Study

Population Study

Ongoing 20+ year study tracking HPV vaccination outcomes and cervical cancer prevention in vaccinated cohorts.

Instituto Nacional de Cancerología
Ongoing enrollment

Breast Cancer Precision Medicine

Phase 2

Tailoring breast cancer treatments based on genetic testing for Mexican women with BRCA and other mutations.

Centro Médico Nacional Siglo XXI
Active recruitment

Want to learn about more Mexican clinical trials? Search our database or contact our team.

Clinical Trials in Mexico

Registry-listed trials for Mexico currently tracked in our database, sourced from public trial registries.

Efficacy of Oral or Topical Catechins vs. Placebo as an Adjuvant for the Prevention and Management of Radiation Dermatitis in Oncology Patients: a Randomized Trial

Phase III
Enrolling by invitation
NCT07149506
View registry record

Efficacy of Oral or Topical Catechins vs. Placebo as an Adjuvant for the Prevention and Management of Radiation Dermatitis in Oncology Patients: a Randomized Trial

Phase III
Enrolling by invitation
NCT07149506
View registry record

Efficacy of Oral or Topical Catechins vs. Placebo as an Adjuvant for the Prevention and Management of Radiation Dermatitis in Oncology Patients: a Randomized Trial

Phase III
Enrolling by invitation
NCT07149506
View registry record

Efficacy of Oral or Topical Catechins vs. Placebo as an Adjuvant for the Prevention and Management of Radiation Dermatitis in Oncology Patients: a Randomized Trial

Phase III
Enrolling by invitation
NCT07149506
View registry record

Efficacy of Oral or Topical Catechins vs. Placebo as an Adjuvant for the Prevention and Management of Radiation Dermatitis in Oncology Patients: a Randomized Trial

Phase III
Enrolling by invitation
NCT07149506
View registry record

Efficacy of Oral or Topical Catechins vs. Placebo as an Adjuvant for the Prevention and Management of Radiation Dermatitis in Oncology Patients: a Randomized Trial

Phase III
Enrolling by invitation
NCT07149506
Radiation Dermatitis Acute
Radiation Dermatitis
Fibrosis; Skin
View registry record

Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase II
Recruiting
NCT07451652
View registry record

Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase II
Recruiting
NCT07451652
View registry record

Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase II
Recruiting
NCT07451652
View registry record

Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase II
Recruiting
NCT07451652
View registry record

Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase II
Recruiting
NCT07451652
View registry record

Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase II
Recruiting
NCT07451652
Relapsed/Refractory Diffuse Large B Cell Lymphoma
View registry record

Latest Research Ecosystem Developments

Mexico — Mexico is increasingly integrating into the global oncology research landscape through participation in multi-regional clinical trials and the coordination of national cancer control strategies.

Updated October 17, 2026

Global Expansion of the ERASur Clinical Trial

The NCI-sponsored Phase III ERASur trial (Alliance A022101) for colorectal cancer has officially expanded into Mexico, allowing for greater international collaboration and access to personalized treatment strategies for diverse patient populations.

Alliance for Clinical Trials in Oncology / OncoDaily

National Cancer Control Program Coordination

Mexico's National Institute of Cancer (INCan) continues to lead the National Cancer Control Program, coordinating a network of 25 State Cancer Centers to standardize oncological guidelines and improve early detection and prevention strategies nationwide.

Secretaría de Salud, Gobierno de México

Challenges in Latin American Clinical Trial Participation

Recent research highlights that while oncology advances are driven by clinical trials, less than 5% of global cancer trials currently recruit patients in Latin America, prompting calls for more inclusive trial designs in the region.

Nature Reviews Clinical Oncology

Advancements in Multi-Regional Clinical Trial Frameworks

A 2025 roundtable convened by the Reagan-Udall Foundation for the FDA addressed the complexities of global oncology trials, emphasizing the need for improved infrastructure to manage the rising data volume and costs associated with multi-regional research.

Reagan-Udall Foundation for the FDA

This section is refreshed on a recurring schedule. Entries are AI-assisted research signals organized from public oncology sources and should be verified against the original sources. Information is educational and does not constitute medical advice.

Huippu Prodigy Platforms

© 2026 Huippu Prodigy Platforms, LLC.

CS Cancer Solutions is operated by Huippu Prodigy Platforms, LLC.

Public-Source Oncology Research • Educational and Research Use

Structured Oncology Research Intelligence